Phenotypic and genotypic diversity in a multinational sample of drug-resistant Mycobacterium tuberculosis isolates

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 4, 2015, Pages 420-427

  Garfein, R S ^a   Catanzaro, D G ^b   Rodwell, T C ^a   Avalos, E ^c   Jackson, R L ^a   Kaping, J ^a   Evasco, H ^d   Rodrigues, C ^e   Crudu, V ^f   Lin, S Y G ^g   Groessel, E ^c   Hillery, N ^c   Trollip, A ^h   Ganiats, T ^c   Victor, T C ^h   Eisenach, K ⁱ   Valafar, F ^j   Channick, J ^a   Qian, L ^k   Catanzaro, A ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF ARKANSAS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Tropical Disease Foundation Inc Philippine Institute of Tuberculosis Building   (Philippines)

^e P D HINDUJA NATIONAL HOSPITAL   (India)

^f Microbiology and Morphology Laboratory   (Moldova)

^g CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^h STELLENBOSCH UNIVERSITY   (South Africa)

ⁱ UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^j SAN DIEGO STATE UNIVERSITY   (United States)

^k UNIVERSITY OF HAWAII   (United States)

more..

Author keywords

Diagnostics; Drug susceptibility testing; Epidemiology; Genotype; Repository

Indexed keywords

AMIKACIN; CAPREOMYCIN; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG RESISTANT TUBERCULOSIS; FEMALE; GENETIC VARIABILITY; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MOLDOVA; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPIC VARIATION; PHILIPPINES; PRIORITY JOURNAL; SOUTH AFRICA; CHILD; DRUG EFFECTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PHENOTYPE; PRESCHOOL CHILD; SPUTUM; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; GENOTYPE; HUMANS; INDIA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLDOVA; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PHILIPPINES; SOUTH AFRICA; SPUTUM; YOUNG ADULT;

EID: 84925679009     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0488     Document Type: Article

References (28)

1. World Health Organization. Global tuberculosis control:WHO report, 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
2. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report, 2005. WHO/HTM/TB/2005.349. Geneva, Switzerland: WHO, 2005.
3. World Health Organization. Global tuberculosis report. WHO report, 2013. WHO/HTM/TB/2013.11. Geneva, Switzerland. WHO, 2013.
4. Kapp C. XDR tuberculosis spreads across South Africa. Lancet 2007; 369: 729-729.
5. Udwadia Z F, Amale R A, Ajbani K K, et al. Totally drugresistant tuberculosis in India. Clin Infect Dis 2012; 54: 579-581.
6. Velayati A A, Masjedi M R, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009; 136: 420-425.
7. Migliori G B, De Iaco G, Besozzi G, et al. First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill 2007; 12: e070517.1.
8. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380: 1406-1417.
9. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report, 2008. WHO/HTM/TB/2008.393. Geneva, Switzerland. WHO, 2008.
10. Isaakidis P, Cox H S, Varghese B, et al. Ambulatory multidrugresistant tuberculosis treatment outcomes in a cohort of HIVinfected patients in a slum setting in Mumbai, India. PLOS ONE 2011; 6: e28066.
11. Ajbani K, Rodrigues C, Shenai S, et al. Mutation detection and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India. J Clin Microbiol 2011; 49: 1588-1590.
12. World Health Organization. Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO report, 2010. WHO/HTM/TB/2010.3. Geneva, Switzerland. WHO, 2010.
13. Philippine Nationwide Tuberculosis Drug Resistance Survey. Nationwide drug resistance survey of tuberculosis in the Philippines. Int J Tuberc Lung Dis 2009; 13: 500-507.
14. Khanna A, Raj V S, Tarai B, et al. Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. Antimicrob Agents Chemother 2010; 54: 4789-4793.
15. Siddiqi S, Rüsch-Gerdes S, Alexander H, et al. MGIT Procedure Manual For BACTEC™ MGIT 960™ TB System. Geneva, Switzerland: Foundation for Innovative New Diagnostics, 2006.
16. World Health Organization. Policy guidance on drug susceptibility testing (DST) of second-line antituberculosis drugs: WHO report, 2008. WHO/HTM/TB/2008.392. Geneva, Switzerland. WHO, 2008.
17. Rodrigues C, Jani J, Shenai S, et al. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System. Int J Tuberc Lung Dis 2008; 12: 1449-1455.
18. Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol 1997; 35: 907-914.
19. Cowan L S, Diem L, Monson T, et al. Evaluation of a two-step approach for large-scale, prospective genotyping of Mycobacterium tuberculosis isolates in the United States. J Clin Microbiol 2005; 43: 688-695.
20. Mazars E, Lesjean S, Banuls A L, et al. High-resolution minisatellite-based typing as a portable approach to global analysis of Mycobacterium tuberculosis molecular epidemiology. Proc Natl Acad Sci U S A 2001; 98: 1901-1906.
21. Shabbeer A, Ozcaglar C, Yener B, et al. Web tools for molecular epidemiology of tuberculosis. Infect Genet Evol 2012; 12: 767-781.
22. Aminian M, Couvin D, Shabbeer A, et al. Predicting Mycobacterium tuberculosis complex clades using knowledge-based Bayesian networks. BioMed Res Int 2014; 2014, 398484.
23. Rodwell T C, Valafar F, Douglas J, et al. Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations. J Clin Microbiol 2014; 52: 781-789.
24. Ajbani K, Grace Lin S Y, Rodrigues C, et al. Evaluation of pyrosequencing for detecting extensively drug-resistant tuberculosis (XDR-TB) in clinical isolates from four highburden countries. Antimicrob Agents Chemother 2015; 59: 414-420.
25. European Concerted Action on New Generation Genetic Markers and Techniques for the Epidemiology and Control of Tuberculosis. Beijing/W genotype Mycobacterium tuberculosis and drug resistance. Emerg Infect Dis 2006; 12: 736-743.
26. Gandhi N R, Moll A, Sturm A W, et al. Extensively drugresistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
27. Supply P, Allix C, Lesjean S, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 4498-4510.
28. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drugresistant tuberculosis, 2014. WHO/HTM/TB/2014.11. Geneva, Switzerland: WHO, 2014.